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Introduction
Ecotropic viral integration site 1 (EVI1) is an evolu-
tionarily conserved gene with important roles both in
malignant diseases and in normal development [1].
Its homozygous disruption in mice led to multiple
malformations, including small or missing limb buds,
defects in the development of the central and periph-
eral nervous systems and an immature heart.
Evi1)⁄) mice died before 11.5 days postcoitum due
to heart failure and massive haemorrhaging [2]. EVI1
is thought to exert its biological effects mainly by
acting as a regulator of gene transcription [1]. It
codes for a 1051 amino acid nuclear protein with
two sets of zinc ﬁnger domains that contain seven
and three zinc ﬁnger motifs, respectively, are able to
bind to DNA independently of each other, and are
separated from each other by an intervening region
(IR) and a transcription repression domain (RD). At
the C-terminus of EVI1, an acidic region (AR)
involved in transcription activation is present [1].
EVI1 interacts with transcriptional coactivators and
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Ecotropic viral integration site 1 (EVI1) plays important roles in leukaemia
and development, and its expression is temporally and spatially highly
restricted during the latter process. Nevertheless, the only physiological
agent that to date has been shown to regulate transcription of this gene in
mammalian cells is all-trans retinoic acid. Here we describe the identiﬁca-
tion of a retinoic acid response element that was located in the most distal
of several alternative ﬁrst exons of the human EVI1 gene and was constitu-
tively bound by canonical retinoid receptors in NTERA-2 teratocarcinoma
cells. Furthermore, it was the target of negative feedback by EVI1 on the
induction of its own promoter by retinoic acid. This process required a pre-
viously described transcription repression domain of EVI1. Extending its
role as a modulator of the retinoic acid response, EVI1 had the opposite
effect on the RARb retinoic acid response element, whose induction by
all-trans retinoic acid it enhanced through a mechanism that involved
almost all of its known functional domains. Augmentation of the retinoic
acid response by EVI1 was also observed for the endogenous RARb gene.
Thus, we have established EVI1 as a novel type of modulator of the reti-
noic acid response, which can both enhance and repress induction by this
agent in a promoter-speciﬁc manner.
Abbreviations
AR, acidic region; ATRA, all-trans retinoic acid; ChIP, chromatin immunoprecipitation; CtBP, C-terminal binding protein; DR, direct repeat;
EVI1, ecotropic viral integration site 1; HA, hemagglutinin; IR, intervening region; NLS, nuclear localization sequence; RA, retinoic acid; RAR,
retinoic acid receptor; RARE, retinoic acid response element; RD, repression domain; RTQ-RT-PCR, real-time quantitative RT-PCR; RXR,
retinoid X receptor; ZF1, zinc ﬁnger domain 1; ZF2, zinc ﬁnger domain 2.
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gene transcription [3–7]. However, so far only very
few direct EVI1 target genes have been described
[7,8] and EVI1 may exert its effects in part by modi-
fying the activity of other sequence-speciﬁc transcrip-
tion factors [9–12].
The human EVI1 gene has several different ﬁrst
exons, whose alternative use gives rise to the transcript
variants EVI1_1a, EVI1_1b, EVI1_1c, EVI1_1d, and
EVI1_3L (Fig. 1A) [1,13–15]. The transcriptional start
sites and the putative regulatory regions of these
mRNA variants are located in close vicinity to each
other, and they are all predicted to be translated into
the same 1051 amino acid protein [14]. In contrast, the
mRNA variant MDS1⁄EVI1 gives rise to an EVI1
protein with an extension of 188 amino acids at its
N-terminus [16,17], which, at least in some experi-
mental systems, acted differently from, and even in an
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Fig. 1. Induction of different EVI1 mRNA and protein variants in response to ATRA in NTERA-2 cells. (A) Schematic of the human EVI1 gene
and its mRNA splice and 5¢-end variants. Boxes, exons; lines, introns. The upper panel shows the entire EVI1 gene, with alternative splicing
producing the D324 mRNA variant indicated by triangular lines. Asterisk and diamond, positions of the start codon in exon 3 and of the stop
codon in exon 16, respectively. In the lower panel, only the 5¢-end of the gene with several alternative ﬁrst exons is shown. The alternative
ﬁrst exon contained within EVI1_1a is exon 1a, etc. Reproduced with permission from [1]. (B) NTERA-2 cells were treated with 10 lM ATRA
or an equivalent amount of dimethylsulfoxide for the indicated periods of time. RNA was extracted and reverse transcribed, and the mRNA
levels of cEVI1 (i.e. the sum of all EVI1 transcripts, ampliﬁed using forward and reverse primers located in exons 7 and 8⁄9, respectively;
black columns), EVI1_1a (white columns), EVI1_1b (horizontally striped columns), EVI1_1d (diagonally striped columns), EVI1_3L (checked
columns) and MDS1⁄EVI1 (stippled columns) were assayed by RTQ-RT-PCR. The expression of each EVI1 mRNA variant relative to the
housekeeping gene cyclophilinD and the 0 h time point, as well as standard deviations between replicate measurements, were calculated
using the DDCT method [45]. Please note that because the DDCT method relates expression values to the 0 h time point for each amplicon,
only induction factors, but not expression levels, can be compared between different amplicons. (C) NTERA-2 cells were treated with the
indicated amounts of ATRA or dimethylsulfoxide for 15 h. RTQ-RT-PCR for cEVI1 was performed as described above. (D) NTERA-2 cells
were treated with 10 lM ATRA or an equivalent amount of dimethylsulfoxide for the indicated periods of time. Proteins were extracted and
subjected to immunoblot analysis using an antibody against EVI1, or a b-tubulin antibody as a loading control. The EVI1 antibody detected
three bands whose molecular masses corresponded to those of MDS1⁄EVI1 ( 170 kDa), EVI1 ( 140 kDa) and of the protein product of
an internal splice variant of EVI1, D324 ( 100 kDa).
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[3,18–20]. The MDS1⁄EVI1 transcript consists of parts
of the mRNA from the MDS1 gene, joined to the sec-
ond exon of the EVI1 mRNA [16,17]. The ﬁrst exon
of MDS1, and therefore also its presumptive regula-
tory regions, are located more than 500 kb upstream
of EVI1 exon 1a. Despite this, the expression patterns
of MDS1⁄EVI1 resembled those of the other EVI1
mRNA variants in almost all investigated human and
murine tissues [14,17].
Although EVI1 was expressed in a temporally and
spatially highly restricted manner during mammalian
development [2,21], the only physiological agent that
to date has been identiﬁed as potentially contributing
to this regulation is all-trans retinoic acid (ATRA)
[14,22,23]. Interestingly, mice with a homozygous dis-
ruption of the retinaldehyde dehydrogenase-2 gene,
which is responsible for embryonic retinoic acid (RA)
synthesis, die on the same day of embryonic develop-
ment as Evi1)⁄) mice, with a partially overlapping
phenotype [2,24]. Like EVI1 [2,22], ATRA also regu-
lates many aspects of neuronal differentiation [25].
Together, these observations suggest that EVI1 may be
involved in mediating some of the biological effects of
ATRA.
RA regulates gene expression by binding to nuclear
receptors that directly act as transcription factors at
the promoters of target genes. Two classes of retinoid
receptors have been described: retinoic acid receptors
(RARs) and retinoid X receptors (RXRs). Each recep-
tor class has three paralogous members in human cells,
designated a, b and c [26,27]. Gene regulation by RA
is usually mediated by heterodimers between one mem-
ber of each of the RAR and the RXR families. These
bind to retinoic acid response elements (RAREs) that
consist of two direct repeats (DR) of the consensus
sequence PuG(G⁄T)TCA, separated by one, two or,
most commonly, ﬁve spacer nucleotides, and accord-
ingly termed DR1, DR2 or DR5 elements. RAR and
RXR bind to their cognate response elements in a con-
stitutive manner. In the absence of RA, they repress
target gene transcription, whereas ligand binding acti-
vates target promoters by inducing conformational
changes in the receptors that lead to replacement of
corepressors by coactivators [26,27]. Numerous genes
have been reported to be regulated by retinoid recep-
tors in a direct manner [28]. In addition, RARs and
RXRs have featured both synergistic and antagonistic
interactions with other sequence-speciﬁc transcription
factors [26].
EVI1 was induced by ATRA in several human and
murine cell lines, and this induction was at least in
part due to an increased rate of transcription
[14,22,23]. Nevertheless, so far no RARE has been
found in the regulatory regions of the EVI1 gene [22].
Here we describe the identiﬁcation of a functional
RARE that is located in exon 1a of the human EVI1
gene, that binds to retinoid receptors in a constitutive
manner, and whose induction by ATRA is inhibited
by EVI1. Furthermore, we show that EVI1 augments
the induction of the RARb gene by ATRA.
Results
Induction of different EVI1 mRNA and protein
variants by ATRA in NTERA-2 cells
To characterize the regulation of the EVI1 gene by
ATRA, NTERA-2 cells were incubated with 10 lm of
this agent for various periods of time, and the expres-
sion of EVI1 and its mRNA 5¢-end variants (except
for EVI1_1c, whose levels are too low for reliable
detection [13,14]) was measured by real-time quantita-
tive RT-PCR (RTQ-RT-PCR). EVI1_1a, EVI1_1b,
EVI1_1d and EVI1_3L (Fig. 1A), as well as the cEVI1
amplicon (which extends from the 3¢-end of exon 7 to
the 5¢-end of exon 9, and thus represents all EVI1
transcript variants, Fig. 1A) were induced by ATRA
to varying extents, but with similar kinetics: their levels
were elevated as early as 3 h after the addition of
ATRA, continued to rise until after 48 h, and then
remained constant until at least 96 h after ATRA addi-
tion (Fig. 1B). The MDS1⁄EVI1 mRNA, in contrast,
began to slightly increase in abundance 24 h after the
addition of ATRA, was distinctly induced at 48 h and
further accumulated up to the 96 h time point
(Fig. 1B).
In a dose–response experiment, cEVI1 was strongly
induced by as little as 10 nm ATRA and reached maxi-
mal levels at 1 lm ATRA (Fig. 1C).
Immunoblot analyses of extracts prepared from
NTERA-2 cells treated with 10 lm ATRA for vari-
ous periods of time revealed three bands speciﬁcally
recognized by an EVI1 antibody (Fig. 1D). The
molecular masses of these bands were consistent with
those reported for MDS1⁄EVI1 ( 170 kDa), EVI1
( 140 kDa) and the protein product of an alterna-
tively spliced EVI1 mRNA, D324 ( 100 kDa)
[16,29]. The 140 kDa band, which gave the strongest
signal, began to appear 12–24 h after the addition of
ATRA and increased in intensity up to the 96 h
time point. The 100 kDa band was considerably fain-
ter, but exhibited similar induction kinetics. The
170 kDa band was the faintest, and was detectable
only at the 72 and 96 h time points (Fig. 1D). The
immunoblot and RTQ-RT-PCR analyses consistently
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upon incubation of NTERA-2 cells with ATRA,
whereas MDS1⁄EVI1 was upregulated with delayed
kinetics.
An inverted DR5 RARE in EVI1 exon 1a confers
ATRA responsiveness to the EVI1 promoter
and binds canonical retinoid receptors in a
constitutive manner
To search for a RARE in the putative regulatory
regions of the human EVI1 gene, three fragments that
together covered most of the genomic region from
positions )2.6 to +3.9 kb relative to the 5¢-end of
EVI1 exon 1a were cloned into the luciferase reporter
vectors pGL3basic and pGL3promoter (Fig. 2A). Only
EVI1(+15⁄+1106)⁄pGL3, whose insert largely corre-
sponds to EVI1 exon 1a, but not EVI1()2629⁄)72)⁄
pGL3 or EVI1(+1258⁄+3903)⁄pGL3, responded to
ATRA in reporter gene assays (Fig. 2A, and data not
shown). Because pGL3basic- and pGL3promoter-based
constructs yielded comparable results, subsequent
experiments were performed only with pGL3basic.
Deletion of the ﬁrst 240 nucleotides of EVI1(+15⁄
+1106)⁄pGL3 completely eliminated the ATRA
response (Fig. 2B), suggesting that it was mediated
by the inverted DR5 RARE consensus sequence
CGACCTTTTTGTGACCT present between nucleo-
tide positions +182 and +198 relative to the begin-
ning of exon 1a. Indeed, EVI1(+86⁄+274)⁄pGL3
was still responsive to ATRA. The importance of
the RARE consensus sequence in conferring ATRA
responsiveness to the EVI1 promoter was corroborated
through mutation of the six residues comprising its
second half-site, which yielded EVI1(+86⁄+1106)-
mut⁄pGL3. This construct did not exhibit any ATRA
response (Fig. 2B). However, its basal activity was ele-
vated as compared with that of the corresponding
wild-type construct (Fig. 2B), probably due to the loss
of repression by unliganded RARs and RXRs [27].
To conﬁrm that the EVI1 RARE was located within
the transcribed region of the EVI1 gene, RT-PCR with
primers surrounding the RARE (Table S1B) was per-
formed on DNAse-treated RNA from NTERA-2 cells
that had been incubated with ATRA or vehicle for
72 h. The RARE amplicon was elevated in response to
ATRA (Fig. 2C), demonstrating that ATRA-induced
transcription of the EVI1 gene indeed initiates in part
or entirely upstream of its RARE.
Chromatin immunoprecipitation (ChIP) experiments
revealed that RARa and RXR were associated with
the EVI1 RARE both in the absence and presence of
ATRA (Fig. 2D). Conﬁrming the speciﬁcity of these
interactions, only faint bands were observed when neg-
ative control immunoprecipitates or primers were used
(Fig. 2D). Similar results were obtained for the RARE
of the RARb gene promoter, which was employed as a
positive control (Fig. 2D). In summary, the ﬁrst exon
of the EVI1 gene contains a consensus RARE motif
that is bound by canonical RARs and RXRs, which
repress it in the absence and activate it in the presence
of ligand.
ATRA regulates the MDS1⁄EVI1 promoter neither
directly, nor through EVI1
Because ATRA induced the MDS1⁄EVI1 mRNA only
slowly (Fig. 1B), its action on the MDS1⁄EVI1 pro-
moter seemed unlikely to be direct. Indeed, none of
four overlapping fragments, which together covered
the genomic region from position )3.0 to +2.5 kb rel-
ative to the transcriptional start site of MDS1⁄EVI1,
conferred responsiveness to treatment with ATRA for
24 or 48 h to a luciferase reporter (Fig. 3A, and data
not shown). We therefore asked whether ATRA might
regulate the slowly responding MDS1⁄EVI1 promoter
in an indirect manner through the rapidly induced
EVI1 protein. However, none of the MDS1⁄EVI1 pro-
moter fragments was induced by exogenously
expressed EVI1, either in the absence or in the pres-
ence of ATRA (Fig. 3A). Therefore, even though
ATRA clearly induces MDS1⁄EVI1, the mechanism
through which it does so remains unclear at present.
pERE⁄luc served as a positive control for the effects
of EVI1 in the reporter assays, and showed the
expected decrease in luciferase activity upon ectopic
expression of EVI1 (Fig. 3A). Notably, ATRA also
reduced the activity of pERE⁄luc (Fig. 3A), probably
through its ability to upregulate the expression of
endogenous EVI1. This supports the assumption that
EVI1 protein induced by ATRA in NTERA-2 cells is
functional as a transcriptional regulator. Interestingly,
ATRA induction of EVI1(+86⁄+1106)⁄pGL3, which
was included in the experiment as a positive control for
the ATRA response, was strongly reduced in the pres-
ence of exogenously expressed EVI1 (Fig. 3A), suggest-
ing negative feedback by EVI1 on its own promoter.
Both EVI1 and MDS1⁄EVI1 counteract the ATRA
response of the EVI1 promoter, but enhance that
of the RARb RARE
As with EVI1(+86⁄+1106)⁄pGL3, the ATRA
response of EVI1(+86⁄+274)⁄pGL3 was strongly
reduced by exogenously expressed EVI1 (Fig. 3B). This
indicated that EVI1 may interfere directly with the
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Fig. 2. A functional RARE is located in exon 1a of the human EVI1 gene. (A) Schematic of the genomic region at the 5¢-end of the human
EVI1 gene and of the fragments cloned into pGL3basic, and luciferase reporter assays. Stippled line, EVI1 upstream region; grey boxes,
exons (exons 1b and 1c are too small to be depicted in this schematic); solid lines, introns. The positions of cloned fragments are indicated
relative to the transcriptional start site of EVI1_1a (GenBank accession no. BX640908). pRARE-tk-luc contains two copies of the human
RARb RARE and the tk minimal promoter in pGL2, and was used as a positive control for the ATRA response. For luciferase assays, the indi-
cated reporter plasmids were transfected into NTERA-2 cells, together with the renilla luciferase plasmid pRL; 10 lM ATRA or an equivalent
amount of dimethylsulfoxide was added 1 day after transfection. Another  24 h later, cells were lysed and luciferase activities were
measured. Relative luciferase units (RLU) were derived by normalizing ﬁreﬂy to renilla luciferase activities. Error bars represent the standard
deviations between duplicate measurements. White bars, dimethylsulfoxide; black bars, ATRA. (B) Schematic of EVI1(+15⁄+1106)⁄pGL3
and its derivative constructs, and luciferase reporter assays. Grey box, exon 1a; black boxes, predicted RAREs. In EVI1(+86⁄+1106)-
mut⁄pGL3, the six nucelotides comprising the second half-site of the EVI1 RARE were mutated (indicated by a cross). Luciferase reporter
gene assays were performed as in (A). (C) RT-PCR conﬁrming that the RARE of the EVI1 gene is located within its transcribed region.
NTERA-2 cells were incubated with ATRA for 0 or 72 h. RNA was extracted, treated with DNaseI, reverse transcribed and ampliﬁed using
primers ﬂanking the EVI1 RARE (EVI1_RARE-F, EVI1_RARE-R; Table S1B), an intron-spanning primer pair located in a more proximal region
of EVI1_1a (EVI1_1a-fwd, EVI1_1a-rev; Table S1A) and a primer pair for the housekeeping gene cyclophilinD (cycD-F, cycD-R; Table S1A).
The effectiveness of the DNaseI treatment was veriﬁed with primers for the microsatellite marker D22S686 (D22S686-F, D22S686-R; Table
S1B). (D) ChIP was performed on NTERA-2 cells treated with ATRA or dimethylsulfoxide for 24 h using an antibody speciﬁc to RARa,a
pan-RXR antibody, or unspeciﬁc rabbit IgG as a negative control. Immunoprecipitated chromatin and input DNA as a positive control were
ampliﬁed with primers ﬂanking the EVI1 RARE (EVI1_RARE-F, EVI1_RARE-R; Table S1B), primers for the RARb RARE (RARb_RARE-F,
RARb_RARE-R; Table S1B) or with negative control primers located in EVI1 exon 3L (EVI1_ex3L-F; EVI1_ex3L-R; Table S1B).
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teins at its own promoter. We next asked whether the
repressive effects of EVI1 would extend to other
ATRA responsive genes. Surprisingly, ATRA induc-
tion of pRARE-tk-luc, which contains two copies of
the RARE that is present in the human RARb gene
promoter [30], was not diminished, but rather
enhanced, by EVI1 (Fig. 3C). Like EVI1, MDS1⁄EVI1
also counteracted ATRA induction of the EVI1 pro-
moter and enhanced that of the RARb RARE
(Fig. 3B,C).
Protein domains involved in modulation of the
ATRA response by EVI1
In order to identify regions in the EVI1 protein that
contribute to positive and negative modulation of the
ATRA response, a series of EVI1 deletion constructs
was prepared (Fig. 4A). All constructs had an N-terminal
hemagglutinin (HA) epitope tag, and either retained a
predicted nuclear localization sequence (NLS) in the
IR, or were engineered to contain an NLS. The expres-
sion and nuclear location of the truncated proteins was
conﬁrmed by immunoblot and indirect immunoﬂuores-
cence analyses (Fig. S1).
Deletion of the ﬁrst zinc ﬁnger domain (ZF1), of the
C-terminal AR, or of the AR and the second zinc
ﬁnger domain (ZF2) (Fig. 4A, B: DZF1, DAR and
DAR-ZF2, respectively) did not affect the repressive
effects of EVI1 on the ATRA response of EVI1(+86⁄
+1106)⁄pGL3 (Fig. 4B). However, a mutant with a
C-terminal deletion that removed the RD in addi-
tion to the AR and the ZF2 (Fig. 4A, B: ZF1-IR) was
inactive. Further deletion of the IR to yield a construct
consisting only of the ZF1 (Fig. 4A, B: ZF1-NLS)
even enhanced the ATRA response of the EVI1 pro-
moter (Fig. 4B). A truncated EVI1 protein comprising
only the IR and the RD (Fig. 4A, B: IR-RD) still had
repressive activity, albeit at a reduced level (Fig. 4B).
The RD was thus clearly important for the negative
feedback by EVI1 on its own promoter. It contains
two closely spaced binding sites for the corepressor
protein C-terminal binding protein (CtBP), the more
C-terminal one of which was reported to be function-
ally more important [4,5,31]. Mutation of this site on
the background of the full-length EVI1 protein only
moderately decreased the ability of EVI1 to counteract
the ATRA response, suggesting that CtBP was not
primarily responsible for transcriptional repression by
EVI1 in this context (Fig. 4C).
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Fig. 3. EVI1 does not mediate ATRA regulation of the MDS1⁄EVI1 promoter, but decreases the ATRA response of its own RARE and
enhances that of the RARb RARE. (A) Four genomic fragments, whose positions are indicated relative to the transcriptional start site of the
MDS1⁄EVI1 gene (assumed to be identical to that of the MDS1 gene; GenBank accession no. NM_004991), were cloned into the luciferase
reporter vector pGL3basic. NTERA-2 cells were cotransfected with these reporter constructs, HA-EVI1⁄pEFzeo or empty vector, and the
renilla luciferase vector pRL-SV40. EVI1(+86⁄+1106)⁄pGL3 served as a positive control for the ATRA response; pEREluc, which contains
two copies of an EVI1 DNA binding site, as a positive control for the effects of EVI1; and empty pGL3basic as a negative control. ATRA or
dimethylsulfoxide was added 1 day after transfection, and cells were lysed and luciferase activities determined another  24 h later. Relative
luciferase units (RLU) were derived by normalizing ﬁreﬂy to renilla luciferase activities. Error bars represent the standard deviations between
duplicate measurements. (B, C) Luciferase assays after transfection of NTERA-2 cells with the indicated reporter plasmids and the expres-
sion vectors HA-EVI1⁄pEFzeo or HA-MDS1⁄EVI1⁄pEFzeo were performed as described in (A). pRARE-tk-luc contains two copies of the
RARE of the human RARb gene promoter and the tk minimal promoter in pGL2; pGL2-tk-luc contains only the tk minimal promoter in pGL2.
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enhancing the ATRA response of the RARb RARE,
similar experiments were performed using the pRARE-
tk-luc reporter plasmid. Deletion of the AR (Fig. 4A, D:
DAR) had only a modest effect on the enhancement of
the ATRA response by EVI1, but deletion of both the
AR and the ZF2 (Fig. 4A, D: DAR-ZF2) eliminated it
(Fig. 4D). Likewise, an EVI1 protein devoid of the ZF1
(Fig. 4A, D: DZF1), or constructs encoding only the
ZF1 (Fig. 4A, D: ZF1-NLS), the ZF1 and IR (Fig. 4A,
D: ZF1-IR), or the IR and RD (Fig. 4A, D: IR-RD),
were incompetent to increase the ATRA response of
pRARE-tk-luc (Fig. 4D). Taken together, several or all
EVI1 protein domains contributed to the enhancement
of the ATRA response by this transcription factor.
EVI1 increases the ATRA response of the
endogenous RARb gene in U937T cells
Finally, we asked whether EVI1 would be able to
modulate induction of an endogenous gene by ATRA.
In NTERA-2 cells, endogenous EVI1 was likely to
obscure the effects of experimentally expressed EVI1.
To circumvent this problem, the cell line U937T_
EVI1-HA E10, a U937 derivative that does not express
its own EVI1 gene, but has been engineered to express
exogenous EVI1 in a tetracycline repressible manner
(Fig. 5A) [32], was used. U937T_EP P3 cells, which
contain the corresponding empty plasmid instead of the
EVI1 expression plasmid, served as a negative control.
In U937T_EVI1-HA E10 cells, the RARb mRNA was
undetectable by RTQ-RT-PCR in the absence of
ATRA, but was strongly upregulated by this agent.
Induction of EVI1 by removal of tetracycline led to an
enhancement of this response (Fig. 5B), demonstrating
that EVI1 was indeed able to modulate the ATRA
response of an endogenous gene.
Discussion
Expression of the EVI1 gene is highly regulated during
normal development [2,21,33] and is deregulated in
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little is known about the control of its transcription. In
the present report, we have conﬁrmed induction of the
human EVI1 gene by ATRA, and demonstrated that a
classical inverted DR5 RARE is located within its
transcribed region, near the beginning of exon 1a. This
element was necessary and sufﬁcient to confer ATRA
responsiveness to a luciferase reporter gene. Like other
RAREs [26,27], it was bound by RAR and RXR in a
constitutive manner, and repressed in the absence and
activated in the presence of ligand. In silico analysis
also predicted a DR2 RARE in exon 1 of the MDS1⁄
EVI1 gene. However, neither this element nor any
other sequences in a 5.5 kb region surrounding the
transcriptional start site of MDS1⁄EVI1 were able to
confer ATRA responsiveness to a luciferase reporter
gene. Also, MDS1⁄EVI1 was not regulated by ATRA
indirectly through the rapidly induced EVI1 protein. It
remains possible, however, that regulatory elements
outside the region investigated in this study do indeed
confer direct responsiveness to ATRA and⁄or EVI1 to
the MDS1⁄EVI1 promoter.
Interestingly, we found that the EVI1 RARE not
only mediated transcriptional induction in response to
ATRA, but in addition conferred negative feedback by
EVI1 on its own promoter. On the other hand, EVI1
enhanced the ATRA response of a reporter gene dri-
ven by the RARb RARE, as well as that of the endo-
genous RARb gene. This not only argues against a
nonspeciﬁc squelching effect as an explanation for the
negative feedback of EVI1 on its own promoter, but
also establishes EVI1 as a dual regulator of the ATRA
response, which is able to repress or enhance gene
induction by this agent in a promoter-speciﬁc manner.
Notably, in silico analysis using tfsearch (http://
www.cbrc.jp/research/db/TFSEARCH.html) did not
reveal any EVI1 consensus DNA binding sites overlap-
ping with, or located in the vicinity of, the EVI1 or
the RARb RAREs. Accordingly, ChIP experiments
using either an EVI1 or an HA antibody failed to
reveal an interaction between the EVI1 protein and the
EVI1 or RARb RAREs in native or transfected
NTERA-2 cells, or in U937T_EVI1-HA cells (data not
shown). This may be due to technical problems related
to, for example, antibody quality, epitope accessibility
or the positioning of side chains reactive with cross-
linking reagents. Alternatively, modulation of the
ATRA response by EVI1 may not involve interactions
between EVI1 and DNA. Instead, the induction of
EVI1 and RARb by ATRA may require different
cofactors, and EVI1 may differentially interact with,
and affect the activity of, these cofactors in the nucleo-
plasm.
Not surprisingly, the positive and negative effects of
EVI1 on the ATRA response were mediated through
different protein domains. For the inhibitory effects of
EVI1 on the induction of its own promoter by ATRA,
the region between the two zinc ﬁnger domains was
both necessary and sufﬁcient. This region consists of a
previously established RD [4,5,37] and an IR, which
may also be able to mediate transcriptional repression
[38]. Even though expression of the isolated IR+RD
considerably diminished the ATRA response of the
EVI1 promoter, full repression required the additional
presence of either N-terminally or C-terminally adja-
cent domains. These may contribute in a partially
redundant manner to pertinent interactions between
EVI1 and other proteins, and⁄or be required to
A
B
Fig. 5. EVI1 enhances the ATRA response of the endogenous
RARb gene in U937T_EVI1-HA cells. (A) Immunoblot analysis dem-
onstrating induction of EVI1-HA in U937T_EVI1-HA E10 cells (E10)
48 h after removal of tetracycline (tet) from the culture media.
U937T cells transfected with empty plasmid (U937T_EP P3 cells;
P3) were used as a negative control. EVI1-HA was detected with
an HA antibody; hybridization with an antibody against b-tubulin
was used as a loading control. (B) U937T_EVI1-HA E10 cells (E10)
and U937T_EP P3 cells (P3) were maintained in the presence or
absence of tetracycline and of ATRA for 24 and 48 h. RARb mRNA
levels were determined by RTQ-RT-PCR and related to those of the
housekeeping gene cyclophilinD using the DDCT method [45].
Because RARb expression was undetectable in the absence of
ATRA, the corresponding data are not shown. White and black
columns, cells cultured in the presence or absence of tetracycline,
respectively.
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adopt in the context of the full-length protein. A point
mutation (DL⁄AS) disrupting the functionally more
important of two consensus binding sites for the core-
pressor CtBP in the EVI1 RD [4,5] reduced the nega-
tive modulation of the ATRA response by EVI1.
However, EVI1 DL⁄AS also exhibited a diminished
ability to enhance the ATRA response of the RARb
RARE (data not shown), an activity unlikely to be
mediated by a corepressor. This suggested that the
DL⁄AS mutation may not only affect CtBP binding,
but may also alter the structure of EVI1 and⁄or its
interactions with other proteins. Other corepressors
shown to functionally interact with EVI1, such as
histone deacetylase 1 [6] or the histone methyl transfer-
ase SUV39H1 [39,40], may therefore contribute to, or
mediate, repression of the ATRA response by EVI1.
As for the ability of EVI1 to enhance ATRA induction
of the RARb gene, several of its protein domains
appeared to take part in it. Deletion of the AR, which
had previously been implicated in transcriptional acti-
vation by EVI1 [41,42], only moderately reduced the
activating effect of EVI1 on the RARb RARE. How-
ever, further deletion of the ZF2, or deletion of only
the ZF1, abolished this activity, which therefore
appears to require multiple and complex macromolecu-
lar interactions.
It remains to be determined whether EVI1 modulates
more of the several hundred reported ATRA responsive
genes [28] in a similar manner as the EVI1 or RARb
genes. EVI1 probably indirectly affects the expression
of at least some of them through the increased levels of
RARb it contributes to. Because ATRA-induced tran-
scription of the EVI1 gene itself would probably also be
augmented through this mechanism, a potentially detri-
mental self-amplifying feed-forward loop could ensue.
The negative feedback of EVI1 on the ATRA induction
of its own promoter plausibly serves to prevent such a
self-enhancing regulatory loop.
Our results also shed new light on previous observa-
tions that ectopic expression of EVI1, possibly in con-
cert with low amounts of ATRA naturally present in
sera used for cell culture, mimicked neuronal differen-
tiation of P19 cells in response to exogenously added
ATRA [22], and that targeted disruption of the retinal-
dehyde dehydrogenase-2 and Evi1 genes in mice caused
partially overlapping phenotypes [2,24]: EVI1 appears
to act both as a downstream target of the ATRA
response and as an upstream regulator of it. It may
therefore contribute to the biological effects of ATRA
in a dual manner: ﬁrst, by activating or repressing its
own, direct target genes; and second, by modulating
the expression of retinoid receptor-regulated genes.
Another exciting possibility raised by our results is
that EVI1 overexpressing leukaemias may exhibit
increased sensitivity to ATRA-induced differentiation.
If this presently speculative assumption can be sub-
stantiated by further experiments, new treatment possi-
bilities may emerge for myeloid leukaemia with EVI1
overexpression, a disease entity that is notoriously
resistant to currently used therapeutic regimens
[15,36,43].
Materials and methods
Cell culture
The human teratocarcinoma cell line NTERA-2 (ACC 527)
was obtained from the German Collection of Microorgan-
isms and Cell Cultures, Braunschweig, Germany. It was
cultivated in Dulbecco’s modiﬁed Eagle’s medium (Invitro-
gen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Invitrogen) and 5% horse serum (Invitrogen)
in a humidiﬁed 37  C incubator at 5% CO2. U937T cells,
kindly provided by G. Grosveld, St Jude Hospital, Mem-
phis, TN, USA, had been derived from U937 human histio-
cytic lymphoma cells by stable transfection with a construct
driving tetracycline regulable expression of the tetVP16
fusion protein [44]. Transfection with an expression plasmid
coding for a tetracycline regulable, HA epitope tagged
EVI1 protein or with empty plasmid as a control yielded
U937T_EVI1-HA E10 and U937T_EP P3 cells, respectively
[32]. These were maintained at 37  C and 5% CO2 in
RPMI 1640 medium (Invitrogen) supplemented with 10%
fetal bovine serum, 500 lgÆmL
)1 hygromycin (PAA, Pasch-
ing, Austria), 0.5 lgÆmL
)1 puromycin (Sigma, St Louis,
MO, USA) and 1 lgÆmL
)1 tetracycline (Serva, Heidelberg,
Germany). To induce the expression of EVI1-HA, cells
were washed three times with phosphate-buffered saline
and resuspended in growth media without tetracycline.
ATRA stock solutions contained 10 mm ATRA in dim-
ethylsulfoxide. Unless indicated otherwise, ATRA was used
at ﬁnal concentrations of 10 and 1 lm for NTERA-2 cells
and U937T derivative cell lines, respectively.
RNA isolation, cDNA synthesis and RTQ-RT-PCR
Total RNA was extracted using Trizol (Invitrogen), treated
with RNase-free DNaseI (Invitrogen), and reverse tran-
scribed using random hexamer primers (Invitrogen) and
M-MLV reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions. RTQ-RT-PCR was carried out
in an ABI Prism 7700 Sequence Detection System (Applied
Biosystems, Carlsbad, CA, USA) using the Power SYBR 
GREEN PCR Master Mix (Applied Biosystems) according
to the manufacturer’s instructions. Primers are shown
in Table S1A. All primers exhibited optimal ampliﬁcation
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keeping gene cyclophilinD were carried out in duplicate; all
other assays were carried out in triplicate. Expression values
for the genes of interest relative to cyclophilinD and to a ref-
erence value were determined using the DDCT method [45].
Plasmids
EVI1 promoter fragments )2629⁄)72, +15⁄+1106 and
+1258⁄+3903 (relative to the transcription start site of
EVI1_1a, GenBank accession no. BX640908) were
ampliﬁed from BAC clone RP11-33A1 using Dynazyme
(Finnzyme, Espoo, Finland; a DNA polymerase with
proofreading activity) and primers containing engineered
restriction sites. Similarly, MDS1⁄EVI1 promoter fragments
)2968⁄)1975, )2027⁄)915, )920⁄+357 and +310⁄+2456
(relative to the transcription start site of MDS1, GenBank
accession no. NM_004991) were ampliﬁed from BAC clone
RP11-816J6. PCR products were cloned into pCR
  2.1-
TOPO
  (Invitrogen) and then transferred into the luciferase
reporter plasmid pGL3basic (Promega, Madison, WI, USA).
Initial experiments with the EVI1 promoter fragments were
also carried out with analogous constructs in pGL3promoter,
but as both types of plasmid yielded similar results, subsequent
analyses were restricted to pGL3basic. Deletion subclones of
EVI1(+15⁄+1106)⁄pGL3 were generated through restriction
digestion and religation or through PCR. A mutation that
changed the sequence of the second half-site of the EVI1
RARE from TGACCT to CTTTAG [46] was introduced into
EVI1(+86⁄+1106)⁄pGL3 using overlap extension PCR. The
resulting PCR product was cloned into pCR
  2.1-TOPO
 
(Invitrogen) and then transferred into pGL3basic. Primers and
restriction sites used to generate promoter constructs are
available upon request. pRARE-tk-luc contains two copies of
the RARE of the human RARb gene promoter [30] and a tk
minimal promoter in pGL2 (Promega); the corresponding
empty control vector pGL2-tk-luc is identical except that it
lacks the RAREs. Both plasmids were kindly provided by H.
Harant, Ingenetix, Vienna, Austria. pERE⁄luc consists of two
copies of the recognition sequence for the N-terminal zinc
ﬁnger domain of EVI1, the tk minimal promoter and the
pGL3basic vector backbone [6].
HA-EVI1⁄pEFzeo and HA-MDS1⁄EVI1⁄pEFzeo con-
tain the human EVI1 and MDS1⁄EVI1 cDNAs, respec-
tively, both with an engineered Kozak consensus for
translation initiation and an N-terminal HA epitope tag,
under the control of the eIF1a promoter [6]. To obtain
EVI1 deletion constructs, internal restriction fragments of
HA-EVI1⁄pEFzeo were replaced by suitable PCR prod-
ucts in a manner that left the Kozak sequence and the
HA tag intact. To construct EVI1 ZF1-NLS, a double-
stranded oligonucleotide containing a tandem repeat of
the SV40 large T antigen NLS [47], followed by a stop
codon, and a PCR product covering the EVI1 ZF1 region
and part of the NLS were used as templates in a fusion
PCR. The resulting ZF1-NLS PCR product was cloned
into HA-EVI1⁄pEFzeo as described above. All other dele-
tion constructs retained a predicted NLS in the IR of
EVI1. Primers and restriction sites used to generate EVI1
deletion constructs are available upon request. The human
EVI1 cDNA with the CtBP binding site mutation,
DL⁄AS, and the corresponding wild-type cDNA had been
cloned into pME18S, and were kindly provided by
M. Kurokawa, Tokyo University, Japan [5].
Transient transfections and reporter gene assays
One day before transfection, NTERA-2 cells were seeded
into 24-well plates at a density of 8 · 10
4 cells per well.
Transfections were carried out using DAC-30 (Eurogentec,
Seraing, Belgium; production discontinued) or FuGene6
(Roche, Basel, Switzerland) according to the manufacturers’
instructions, employing 0.6 lg DNA and 2 lL DAC-30, or
0.6 lg DNA and 3 lL FuGene6, per well. Transfection
efﬁciencies were > 25%.
To assess the ATRA responsiveness of the EVI1
promoter fragments, 540 ng of reporter plasmid were
cotransfected with 60 ng of the renilla luciferase plasmid
pRL-TK (Promega). To determine the responsiveness of
reporter plasmids to EVI1, its deletion derivatives or
MDS1⁄EVI1, 300 ng of reporter plasmid was cotransfected
with 300 ng of the respective expression vector and 6 ng of
the renilla luciferase plasmid pRL-SV40 (Promega). 10 lm
ATRA, or an equivalent amount of dimethylsulfoxide, was
added to each well 1 day after transfection. On day two
after transfection, the cells were lysed, and ﬁreﬂy and renilla
luciferase activities were assayed in an Aureon PhL lumino-
meter (Aureon Biosystems, Vienna, Austria) using the
Dual-Luciferase Reporter Assay System (Promega). Fireﬂy
luciferase activities were normalized to renilla luciferase
activities to adjust for variability in transfection efﬁciencies.
Duplicate samples were assayed for each data point.
ChIP
NTERA-2 cells were cultivated in 15 cm dishes to  80%
conﬂuence and treated with 10 lm ATRA, or an equivalent
amount of dimethylsulfoxide, for 24 h. Proteins were cross-
linked to DNA by incubating the cells with 1% formalde-
hyde (Sigma) for 10 min at 37  C. After quenching with
125 mm glycine (Sigma) for 5 min at room temperature, the
cells were washed with ice-cold phosphate-buffered saline
containing a complete protease inhibitor cocktail (Roche),
scraped off the dishes and lysed in a buffer containing
50 mm Tris pH 8.1, 10 mm EDTA, 1% SDS and a complete
protease inhibitor cocktail (Roche). Chromatin was sheared
with eight cycles of 15 s each at 90% duty cycle on a Bran-
son soniﬁer 450 (Branson, Danbury, CT, USA). Sample
concentrations were normalized based on their A280. Chro-
matin was diluted 1 : 10 into ChIP buffer (OneDay ChIP
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4  C with 8 lg of RARa antibody (sc-551, Santa Cruz, CA,
USA), pan-RXR antibody (sc-774, Santa Cruz) or rabbit
IgG. Further processing was performed using the OneDay
ChIP kit according to the manufacturer’s instructions.
In an aliquot of the sheared chromatin, the cross-link
was reversed by overnight incubation at 65  C with 2%
SDS, 100 mm NaHCO3,1 0m m dithiothreitol and 200 mm
NaCl. After proteinase K digestion, DNA was recovered
by phenol⁄chloroform extraction and ethanol precipitation.
Agarose gel electrophoresis showed a DNA smear ranging
in size from 100 bp to 2 kb, with maximal intensity at
500 bp. Immunoprecipitated DNA and de-crosslinked
(‘input’) DNA as a positive control were subjected to PCR
with primers ﬂanking the EVI1 RARE (EVI1_RARE-F,
EVI1_RARE-R; Table S1B), primers ﬂanking the RARb
RARE (RARb_RARE-F, RARb_RARE-R; Table S1B;
[48]), and with negative control primers located in EVI1
exon 3L (EVI1_ex3L-F, EVI1_ex3L-R; Table S1B).
Immunoblot analysis
For protein extraction, cells were subjected to repeated
freeze–thawing in a buffer containing 20 mm Tris pH 8.0,
100 mm NaCl, 1 mm EDTA, 0.5% NP-40, 0.5 mm phen-
ylmethanesulfonyl ﬂuoride and a complete protease inhibi-
tor cocktail (Roche). Denaturing PAGE, tank blotting onto
Bio Trace NT nitrocellulose membranes (Pall Corporation,
Port Washington, NY, USA) and antibody hybridizations
were performed using standard procedures. Primary anti-
bodies directed against the HA-tag (mouse anti-HA.11
clone 16B12; Covance, Berkeley, CA, USA), EVI1 (rabbit
anti-EVI1 C50E12; Cell Signaling Technology, Danvers,
MA, USA) or b-tubulin (mouse anti-b-tubulin clone TUB
2.1; Sigma) were used at dilutions of 1 : 10000, 1 : 1000
and 1 : 2500, respectively. Horseradish peroxidase-conju-
gated goat anti-mouse and goat anti-rabbit secondary IgGs
were used at dilutions of 1 : 40000–1 : 100000, and detected
using the Super Signal West Femto kit (Pierce, Rockford,
IL, USA).
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